Paige has launched a new artificial intelligence (AI)-based digital assay to identify and diagnose microsatellite instability (MSI) status in colon cancers.

Part of the company’s Colon Suite, the new Paige Colon MSI can run on whole slide images of haematoxylin and eosin-stained slides alone.

It enables a slide-level classification of MSI status in colon cancer samples.

Paige biomarker development medical director Dr Joe Oakley said: “Paige Colon MSI is another example of how the company is innovating to empower pathologists, transform pathology and improve the lives of patients with cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We used the most advanced machine learning methods available on the most robust dataset in the industry to improve AI detection of MSI in colon cancer.

“We hope to demonstrate that this assay will offer laboratories and healthcare systems a chance to reduce MSI screening costs and accelerate their workflows.”

Pathologists using the new assay can benefit from additional insight into identifying patients who could benefit from definitive MSI/MMR testing, which is crucial to detect common hereditary cancer syndrome and provide immuno-oncology therapy.

Paige has specifically designed the system for optimal negative predictive value.

It supports the immediate generation of AI results from digitised stained sections, thereby reducing diagnostic turnaround times.

Paige became the first company to secure approval from the US Food and Drug Administration for a clinical AI application in digital pathology when it received de novo marketing authorisation for its Paige Prostate Detect in September 2021.